Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21782823 | 0.86 | CA9 (0.35) | CA9CA12CA2FUCA1 | |
| SCHEMBL13699579 | 0.84 | CA2 (0.38) | CA9CA12CA2FUCA1 | |
| SCHEMBL13887631 | 0.84 | CA2 (0.38) | CA9CA12CA2FUCA1 | |
| SCHEMBL13498556 | 0.84 | CA2 (0.38) | CA9CA12CA2FUCA1 | |
| SCHEMBL16327272 | 0.84 | CA2 (0.38) | CA9CA12CA2FUCA1 | |
| SCHEMBL13824425 | 0.82 | — | — | |
| SCHEMBL19808033 | 0.74 | FUCA1 (0.41) | CA9CA12CA2FUCA1 | |
| SCHEMBL13033972 | 0.74 | FUCA1 (0.41) | CA9CA12CA2FUCA1 | |
| SCHEMBL19401511 | 0.72 | M6PR (0.33) | — | |
| SCHEMBL19397196 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213072-A1 | METABOLITES OF GLP1R AGONISTS | PFIZER INC. (US) | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213072-A1 | METABOLITES OF GLP1R AGONISTS | GLP1R, GCGR, GIPR | CA9 1625/4885CA12 3708/4885CA2 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.